In a randomized trial that enrolled 60 treatment-naive patients with hepatitis C virus (HCV)
genotype 1 infection—including those with unfavorable treatment characteristics such as black
race, genotype 1a, advanced liver fibrosis, and obesity—Osinusi and colleagues assessed the
effect of treatment with sofosbuvir in combination with ribavirin on sustained virologic
response—defined as an undetectable HCV viral load assessed 24 weeks after treatment
completion. The authors report that a 24-week regimen of sofosbuvir and weight-based or low-dose
ribavirin resulted in sustained viral response rates of 68% and 48%, respectively.